A new horizon for Sjögren’s disease: the FDA breakthrough designation of ianalumab

Dear Editor, The FDA’s therapy designation for ianalumab (VAY736) represents a significant moment for Sjögren’s disease[1]. This decision is not simply a regulatory breakthrough but a long-awaited indication of progress for a systemic autoimmune condition that affects ~0.25% of the global population, half of whom remain undiagnosed[2]. For decades, patient management has relied on symptomatic relief (artificial tears) and off-label immunomodulators (hydroxychloroquine or corticosteroids) without a single approved therapy to modify the disease course[3,4]. The January 16, 2026 granted designation based on positive NEPTUNUS Phase III evidence, announces a fundamental shift toward targeted treatment and validates a new era of research for this neglected disease[1]. The significance of this development is rooted in compelling clinical data. The nearly 800 patients-based randomized, double-blind, placebo-controlled global NEPTUNUS-1 and NEPTUNUS-2 trials are the first replicate Phase III studies in Sjögren’s to meet their primary endpoint. Ianalumab demonstrated statistically significant improvement in disease activity as measured by the ESSDAI score at Week 48. In NEPTUNUS-1, patients receiving monthly ianalumab (n = 137) showed a mean ESSDAI reduction of −6.4 (SE, 0.47) compared to −5.1 (SE, 0.46) with placebo (n = 138). Whereas, in NEPTUNUS-2, monthly ianalumab (n = 168) achieved a mean reduction of −6.5 (SE, 0.36) versus −5.5 (SE, 0.35) with placebo (n = 169). Critically, secondary analyses displayed clinically meaningful benefits. This includes significant improvements in both physician and patient global assessments in NEPTUNUS-1 [group difference of −0.97 on the ESSPRI (P < 0.001)], indicating a tangible decrease in the daily burden of symptoms like dryness, pain, and fatigue. In NEPTUNUS-2, although patient-reported outcomes improved numerically, the differences did not reach statistical significance, suggesting potential heterogeneity in treatment response[5]. These results are supported by a favorable safety analysis where adverse event rates were comparable to placebo[6] Scientifically, ianalumab’s novel dual mechanism directly addresses known pathophysiology. As a fully human monoclonal antibody, it depletes hyperactive B-cells while simultaneously blocking the BAFF receptor to inhibit B-cell activation and survival. This two-pronged approach against central drivers of autoimmunity offers a more precise therapeutic strategy than previous nonspecific immunosuppressants. The positive trial outcomes confirm the critical role of B-cell dysregulation in Sjögren’s and establish a promising new direction for drug development[7,8]. From a patient-care perspective, the potential impact of Novartis’ ianalumab designation is profound. Rheumatologists have long managed this heterogeneous disease without effective targeted tools. As noted by Janet E. Church of the Sjögren’s Foundation, this development brings concrete hope for a better quality of life to patients who have faced a profound unmet need. Experts in the field recognize that “the landscape of Sjögren’s disease is about to change,” moving clinicians from symptom managers toward disease modifiers[9]. While this breakthrough is reason for optimism, it also opens essential new questions for the scientific community. Future research must identify which patient subsets defined by specific symptom profiles or biomarkers derive the greatest benefit. The extended treatment period required to see that significant effects underscores the need for studies on long-term efficacy and safety. Furthermore, the success of a targeted B-cell therapy offers study into combination strategies and investigation of other pathogenic pathways such as the type I interferon signature or T-cell co-stimulation to develop a more comprehensive treatment collection. In conclusion, the breakthrough designation for ianalumab is a transformative event. It validates a targeted biological approach, responds to an urgent patient need, and fundamentally alters the therapeutic horizon for Sjögren’s disease. This milestone should catalyze further investment and encourage broader scientific discussion and research to fully realize the promise of precision medicine for all patients affected by Sjögren’s disease.